Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30076
Title: | Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single-centre experience | Authors: | Fransen, Lennert D'hondt, Pauline BIELEN, Rob Van den Ende, Natalie ROBAEYS, Geert Peerlinck, Kathelijne Nevens, Frederik |
Issue Date: | 2019 | Publisher: | WILEY | Source: | HAEMOPHILIA, | Abstract: | Introduction Patients with haemophilia are one of the subgroups with a high prevalence of hepatitis C virus (HCV) infection. They are a potential target group to eliminate HCV infection thanks to the availability of direct-acting antiviral (DAA) therapy. Aim To investigate the results of DAA therapy in a cohort of patients with bleeding disorders. Methods This retrospective study was conducted between July 2018 and April 2019. All patients born before 1990 with haemophilia, von Willebrand factor Disease, factor V deficiency, factor VII deficiency or afibrinogenemia were included in this study. Results Of 299 patients, 297 (99.3%) were tested for HCV antibody presence and 211 (71.0%) were positive. Of these, 205 (97.1%) were tested for HCV RNA and 153 (72.1%) were chronically infected. In total, 127 (83.0%) received antiviral therapy, and 110 (71.8%) patients were cured by antiviral treatment. The presence of cirrhosis was significantly higher in patients without a cure for HCV infection when compared to patients who achieved sustained virologic response by treatment or never infected (32.6% vs. 12.8% vs. 0%; P < .001). At the end of follow-up in 2019, only 14 (9.1%) patients had a remaining HCV infection. Ten (71.4%) were lost to follow-up, one (7.1%) patient refused, two (14.2%) had comorbidities and one (7.1%) will start treatment soon. Conclusion In this cohort, the elimination targets for HCV infection in 2030 as proposed by the World Health Organization were already reached. Nevertheless, in order to cure every patient, monitoring tools are necessary. | Notes: | [Fransen, Lennert; D'hondt, Pauline] Katholieke Univ Leuven, Fac Med & Life Sci, Leuven, Belgium. [Bielen, Rob; Robaeys, Geert] Hasselt Univ, Fac Hlth & Life Sci, Hasselt, Belgium. [Bielen, Rob; Robaeys, Geert] Ziekenhuis Oost Limburg, Dept Gastroenterol, Schiepse Bos 6, B-3600 Genk, Belgium. [Van den Ende, Natalie; Robaeys, Geert; Nevens, Frederik] Univ Hosp KU Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium. [Peerlinck, Kathelijne] Haemophilia Ctr Univ Hosp, Dept Vasc Med & Haemostasis, Leuven, Belgium. | Keywords: | bleeding disorders;elimination;haemophilia;hepatitis C virus;treatment | Document URI: | http://hdl.handle.net/1942/30076 | ISSN: | 1351-8216 | e-ISSN: | 1365-2516 | DOI: | 10.1111/hae.13829 | ISI #: | 000484288600001 | Rights: | 2019 John Wiley & Sons Ltd | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fransen_et_al-2019-Haemophilia.pdf Restricted Access | Published version | 618.01 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.